Your browser is no longer supported. Please, upgrade your browser.
Cogent Biosciences, Inc.
Index- P/E- EPS (ttm)-12.41 Insider Own0.56% Shs Outstand34.88M Perf Week-7.41%
Market Cap239.70M Forward P/E- EPS next Y-1.60 Insider Trans-7.40% Shs Float33.94M Perf Month-26.02%
Income-184.80M PEG- EPS next Q-0.36 Inst Own95.63% Short Float6.06% Perf Quarter-30.96%
Sales0.80M P/S299.62 EPS this Y-287.10% Inst Trans10.58% Short Ratio6.58 Perf Half Y-31.58%
Book/sh3.79 P/B1.58 EPS next Y-11.10% ROA-112.10% Target Price- Perf Year-43.40%
Cash/sh5.77 P/C1.04 EPS next 5Y- ROE-292.30% 52W Range6.01 - 14.44 Perf YTD-46.57%
Dividend- P/FCF- EPS past 5Y- ROI-66.40% 52W High-58.45% Beta3.03
Dividend %- Quick Ratio28.20 Sales past 5Y21.40% Gross Margin- 52W Low-0.17% ATR0.42
Employees15 Current Ratio28.20 Sales Q/Q- Oper. Margin- RSI (14)31.38 Volatility5.39% 5.91%
OptionableYes Debt/Eq0.00 EPS Q/Q58.40% Profit Margin- Rel Volume0.89 Prev Close6.24
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume312.35K Price6.00
Recom1.30 SMA20-11.16% SMA50-22.72% SMA200-36.08% Volume279,104 Change-3.85%
Jun-09-21Resumed Jefferies Buy $20
Dec-23-20Initiated Piper Sandler Overweight $22
Oct-14-20Initiated Ladenburg Thalmann Buy $4
Jul-27-21 07:00AM  
Jul-13-21 11:11AM  
Jun-29-21 07:00AM  
Jun-15-21 11:37AM  
May-26-21 07:00AM  
May-12-21 07:00AM  
May-03-21 07:00AM  
Apr-06-21 07:00AM  
Mar-17-21 02:27AM  
Mar-16-21 07:00AM  
Feb-22-21 07:00AM  
Feb-18-21 07:00AM  
Feb-11-21 07:00AM  
Dec-04-20 05:16PM  
Dec-01-20 11:08PM  
Nov-30-20 04:01PM  
Nov-20-20 07:00AM  
Nov-18-20 09:00AM  
Nov-12-20 04:30PM  
Nov-09-20 07:00AM  
Nov-05-20 07:00AM  
Oct-26-20 07:00AM  
Apr-01-20 01:42AM  
Nov-13-19 06:22PM  
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Green John L.Chief Financial OfficerApr 26Sale8.8617,813157,8233,841Apr 28 08:30 PM